These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30894125)

  • 1. A genomic analysis of Mycobacterium immunogenum strain CD11_6 and its potential role in the activation of T cells against Mycobacterium tuberculosis.
    Kaur G; Chander AM; Kaur G; Maurya SK; Nadeem S; Kochhar R; Bhadada SK; Agrewala JN; Mayilraj S
    BMC Microbiol; 2019 Mar; 19(1):64. PubMed ID: 30894125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A lipidated peptide of Mycobacterium tuberculosis resuscitates the protective efficacy of BCG vaccine by evoking memory T cell immunity.
    Rai PK; Chodisetti SB; Zeng W; Nadeem S; Maurya SK; Pahari S; Janmeja AK; Jackson DC; Agrewala JN
    J Transl Med; 2017 Oct; 15(1):201. PubMed ID: 28985739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis.
    Coler RN; Campos-Neto A; Ovendale P; Day FH; Fling SP; Zhu L; Serbina N; Flynn JL; Reed SG; Alderson MR
    J Immunol; 2001 May; 166(10):6227-35. PubMed ID: 11342645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ
    PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BCGΔBCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo.
    Pedroza-Roldán C; Guapillo C; Barrios-Payán J; Mata-Espinosa D; Aceves-Sánchez Mde J; Marquina-Castillo B; Hernández-Pando R; Flores-Valdez MA
    Vaccine; 2016 Sep; 34(40):4763-70. PubMed ID: 27546876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative transcriptomics reveals common and strain-specific responses of human macrophages to infection with Mycobacterium tuberculosis and Mycobacterium bovis BCG.
    Li P; Li Y; Wang CC; Xia LG
    Microb Pathog; 2024 Apr; 189():106593. PubMed ID: 38387847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis.
    Hwang SA; Kruzel ML; Actor JK
    Int Immunopharmacol; 2005 Mar; 5(3):591-9. PubMed ID: 15683854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
    Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.
    Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN
    J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the membrane proteome of virulent Mycobacterium tuberculosis and the attenuated Mycobacterium bovis BCG vaccine strain by label-free quantitative proteomics.
    Gunawardena HP; Feltcher ME; Wrobel JA; Gu S; Braunstein M; Chen X
    J Proteome Res; 2013 Dec; 12(12):5463-74. PubMed ID: 24093440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice.
    McMurry JA; Kimball S; Lee JH; Rivera D; Martin W; Weiner DB; Kutzler M; Sherman DR; Kornfeld H; De Groot AS
    Curr Mol Med; 2007 Jun; 7(4):351-68. PubMed ID: 17584075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
    Majlessi L; Brodin P; Brosch R; Rojas MJ; Khun H; Huerre M; Cole ST; Leclerc C
    J Immunol; 2005 Mar; 174(6):3570-9. PubMed ID: 15749894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative genomics of BCG vaccines by whole-genome DNA microarray.
    Behr MA; Wilson MA; Gill WP; Salamon H; Schoolnik GK; Rane S; Small PM
    Science; 1999 May; 284(5419):1520-3. PubMed ID: 10348738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
    Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
    Front Immunol; 2018; 9():2371. PubMed ID: 30386336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
    Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
    Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines.
    Romano M; Aryan E; Korf H; Bruffaerts N; Franken CL; Ottenhoff TH; Huygen K
    Microbes Infect; 2012 Jan; 14(1):86-95. PubMed ID: 21920450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycobacterium tuberculosis H37Rv: Delta RD1 is more virulent than M. bovis bacille Calmette-Guérin in long-term murine infection.
    Sherman DR; Guinn KM; Hickey MJ; Mathur SK; Zakel KL; Smith S
    J Infect Dis; 2004 Jul; 190(1):123-6. PubMed ID: 15195251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.